Literature DB >> 26196851

Can prokineticin prevent obesity and insulin resistance?

Jean-Jacques Von Hunolstein1, Canan G Nebigil.   

Abstract

PURPOSE OF REVIEW: Because of its increasing prevalence and morbi-mortality, obesity is a major health problem. Obesity etiology includes a combination of excess dietary calories and decreased physical activity, coupled with either predisposing genetic factors or metabolic disorders such as insulin resistance. Adipose tissue secretes several metabolically important proteins known as 'adipokines' that play a major role in obesity and insulin resistance. High levels of a newly identified group of adipokines, called prokineticins, have been found in obese adipose tissues. Prokineticins are peptide hormones released principally from macrophages and reproductive organs. They act on the G protein-coupled receptors PKR1 and PKR2. This review aims to provide an overview of current knowledge of the role of prokineticins and their receptors in the development of obesity and insulin resistance. RECENT
FINDINGS: The principal biological effect of prokineticins in the central nervous system is the control of food intake. Nevertheless, peripheral biological effects of prokineticin are associated with increasing insulin sensitivity and suppressing the adipose tissue expansion.
SUMMARY: We outline the biological significance of the central and peripheral effects of prokineticins, and the potential of their receptors as targets for the treatment of obesity and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26196851     DOI: 10.1097/MED.0000000000000185

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  6 in total

Review 1.  Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.

Authors:  Eva Dolezelova; Evan Stein; Giuseppe Derosa; Pamela Maffioli; Petr Nachtigal; Amirhossein Sahebkar
Journal:  Br J Clin Pharmacol       Date:  2017-03-10       Impact factor: 4.335

2.  Ranking factors involved in diabetes remission after bariatric surgery using machine-learning integrating clinical and genomic biomarkers.

Authors:  Helle Krogh Pedersen; Valborg Gudmundsdottir; Mette Krogh Pedersen; Caroline Brorsson; Søren Brunak; Ramneek Gupta
Journal:  NPJ Genom Med       Date:  2016-10-26       Impact factor: 8.617

Review 3.  Prokineticin Is a New Linker between Obesity and Cardiovascular Diseases.

Authors:  Canan G Nebigil
Journal:  Front Cardiovasc Med       Date:  2017-04-12

4.  Prokineticin receptor-1-dependent paracrine and autocrine pathways control cardiac tcf21+ fibroblast progenitor cell transformation into adipocytes and vascular cells.

Authors:  Rehana Qureshi; Michel Kindo; Himanshu Arora; Mounia Boulberdaa; Marja Steenman; Canan G Nebigil
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

Review 5.  Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.

Authors:  Anais Audebrand; Laurent Désaubry; Canan G Nebigil
Journal:  Front Cardiovasc Med       Date:  2020-01-24

6.  New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans.

Authors:  Marie Mortreux; Ewout Foppen; Raphaël G Denis; Mireia Montaner; Nadim Kassis; Jessica Denom; Mylène Vincent; Frédéric Fumeron; Margaux Kujawski-Lafourcade; Fabrizio Andréelli; Beverley Balkau; Michel Marre; Ronan Roussel; Christophe Magnan; Hirac Gurden; Stéphanie Migrenne-Li
Journal:  Mol Metab       Date:  2019-08-28       Impact factor: 7.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.